Clinical Trial

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Name: Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma — clinical trial record (NCT07438626)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-02-23.

Trial Details

NCT Number	NCT07438626
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Merck Sharp & Dohme LLC
Conditions	Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary Carcinoma
Enrollment	20 participants
Start Date	2026-06-01
Primary Completion	2028-06-01 (estimated)
Study Completion	2030-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-02